# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.
InMode (NASDAQ:INMD) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.44 by 27....
InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, responded to the recent petition to th...
Barclays analyst Matt Miksic maintains InMode (NASDAQ:INMD) with a Overweight and lowers the price target from $34 to $33.
BTL Industries, Inc., a leading provider of innovative medical aesthetic solutions, petitioned the U.S. Patent Office to cancel...
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.